IM Cannabis Explores U.S. Market Entry Following President Trump's Executive Order on Increasing Medical Marijuana and Cannabidiol Research

OG article by IM Cannabis Corp.

January 2, 2026

IM Cannabis Corp. (Nasdaq: IMCC), a medical cannabis company active in Israel and Germany, announced on December 30, 2025, its exploration of opportunities to enter the U.S. cannabis market. This move follows President Donald Trump's executive order signed on December 18, 2025, directing the Attorney General to accelerate rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act. The order recognizes medical benefits while maintaining federal oversight. To support this initiative, IM Cannabis has retained SSC Advisors as exclusive financial advisors to guide U.S. entry strategies, identify potential partners or acquirors, and evaluate possible divestitures of its German and Israeli operations. The company plans to closely monitor developments related to the executive order and the federal rescheduling process. IM Cannabis delivers premium cannabis products to medical patients in Israel and Germany via subsidiaries like Adjupharm GmbH, utilizing a transnational ecosystem, data-driven approaches, and global supply chains to ensure sustainable growth and regulatory compliance. The announcement includes forward-looking statements noting risks associated with potential transactions and evolving regulations, as outlined in the company's annual report dated March 31, 2025. This strategic shift positions IM Cannabis to capitalize on emerging U.S. opportunities in medical cannabis amid changing federal policy.